Related Experiment Videos
[New treatments in cerebrovascular diseases]
1Unidad de Ictus Agudos, Hospital Universitari Doctor Josep Trueta, Girona. adavalose@meditex.es
Insights
Acute stroke care in specialized Stroke Units significantly reduces mortality and dependence. Early thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) offers substantial benefits, while many neuroprotective drugs lack proven clinical efficacy.
Area of Science:
- Neurology
- Emergency Medicine
- Clinical Trials
Context:
- Acute stroke is a time-sensitive neurological emergency requiring specialized care.
- Stroke Units improve patient outcomes by 29% through optimized general therapeutic measures.
- Early intervention is critical for minimizing stroke-related mortality and long-term disability.
Purpose:
- To review current therapeutic strategies for acute ischemic stroke.
- To evaluate the efficacy of thrombolytic therapy, neuroprotective agents, and secondary prevention medications.
- To provide evidence-based recommendations for acute stroke management.
Summary:
- Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) within 3 hours of ischemic stroke onset reduces mortality or dependence by 51%.
- Despite promising animal studies, numerous neuroprotective drugs (e.g., ebselen, citicoline) have failed to demonstrate significant benefits in clinical trials.
- Anticoagulants and antiplatelet agents show limited efficacy in the acute phase; however, clopidogrel and aspirin-dipyridamole combinations are effective for secondary stroke prevention.
Impact:
- Optimized stroke care in dedicated units and timely rt-PA administration can drastically improve patient survival and functional independence.
- Current evidence does not support the routine use of most neuroprotective agents in acute stroke.
- Newer antiplatelet strategies offer improved secondary prevention options for stroke patients.
Abstract:
Acute stroke is a neurologic emergency which should be preferentially treated in a Stroke Unit. The applications of general therapeutic measures in these units decreases the mortality or dependence in 29% of the cases. Thrombolytic treatment with rt-PA in the first 3 hours of cerebral ischemia reduces the risk of mortality or dependence at 3 months by 51%. This treatment should be used in centers with an adequate organization and experience in the management of stroke. Careful patient selection allows a favorable conscious risk/benefit when rt-PA is used in clinical practice. In the last decade numerous neuroprotector drugs have been developed which, despite decreasing the volume of the infarction in animal models, have not currently achieved a reduction in the mortality and morbidity of cerebral infarction in clinical trials. Ebselen, citicoline, piracetam and clomethiazol have shown beneficial effects in preliminary studies or in some subgroups of patients, but their use based on evidence is not recommendable. Anticoagulants and antiplatelet drugs have not been shown to be effective in the acute phase of cerebral infarction. The neuroprotector effect of unfractionated heparin and glycoprotein IIb IIIa antagonists is still under study. Clopidogrel and the association of aspirin and dipiridamol are new alternatives to aspirin in the secondary prevention of cerebral infarction. Both options provide a lower risk of recurrence, and clopidogrel also shows better tolerance. The preventive effect of low intensity anticoagulation and statins is being analyzed in clinical studies.